Mahdi Alzamanan
Papers
1
Total Citations
2
H-Index
1
About
Dr. Mahdi Alzamanan is a pioneering surgical oncologist whose work centers on advancing minimally invasive approaches for peritoneal surface malignancies. His major contributions lie in demonstrating the feasibility and safety of robotic and laparoscopic cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), a traditionally open procedure. His 2024 multicenter study from Saudi Arabia, with 2 citations, represents a landmark effort to establish regional benchmarks for these complex techniques, directly challenging the dogma that such aggressive multimodal treatments require large incisions. By compiling retrospective data across Saudi institutions, Dr. Alzamanan provides critical evidence that minimally invasive CRS/HIPEC can achieve comparable oncologic outcomes while reducing morbidity—a vital step for patients with peritoneal metastasis who otherwise face poor prognoses. This work positions him as a key figure in the global shift toward less invasive surgical oncology, offering hope for improved recovery without compromising survival. His research not only advances surgical technique but also strengthens the evidence base for adopting these approaches in the Middle East, making him a notable contributor to the field.
Research Focus
Key Achievements
Top Papers
- 1